Barclays
FCSC

Barclays’s Fibrocell Science Inc. FCSC Stock Holding History

Barclays’s Portfolio FCSC Stock Details FCSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-196
Closed -$4K – 6908
2016
Q2 		$4K Buy
+196
New +$6.1K ﹤0.01% 5824
2016
Q1 		– Sell
-369
Closed -$22K – 6592
2015
Q4 		$22K Buy
369
+360
+4,000% +$25.9K ﹤0.01% 5165
2015
Q3 		$0 Sell
9
-22
-71% -$1.95K ﹤0.01% 7180
2015
Q2 		$2K Buy
+31
New +$2.09K ﹤0.01% 6859
2014
Q4 		– Sell
-9
Closed – – 7755
2014
Q3 		$0 Sell
9
-354
-98% -$16.6K ﹤0.01% 7917
2014
Q2 		$16K Buy
363
+152
+72% +$8.48K ﹤0.01% 6626
2014
Q1 		$15K Sell
211
-467
-69% -$36.2K ﹤0.01% 6742
2013
Q4 		$41K Sell
678
-21,942
-97% -$1.28M ﹤0.01% 6323
2013
Q3 		$1.36M Buy
22,620
+22,561
+38,239% +$1.82M ﹤0.01% 3020
2013
Q2 		$5K Buy
+59
New +$4.88K ﹤0.01% 7372

Other funds holding FCSC

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's FCSC Position: Q3 2016 in Review

Barclays sold out of Fibrocell Science Inc. (FCSC) in Q3 2016, closing a stake of 196 shares — an estimated $4K sold.

Barclays first reported a position in FCSC in Q2 2013 and held it in 10 quarters. The position peaked at $1.36M in Q3 2013. 37 funds tracked by Wall St. Rank hold FCSC as of Q3 2016.

  • Barclays reported no remaining Fibrocell Science Inc. position as of Q3 2016 after selling out during the quarter.
  • Barclays sold 196 Fibrocell Science Inc. shares in Q3 2016, an estimated $4K.
  • Barclays first reported a position in Fibrocell Science Inc. in Q2 2013 and held it in 10 quarters.
  • Barclays's Fibrocell Science Inc. position peaked at $1.36M in Q3 2013.
  • 37 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q3 2016.

Based on Barclays's 13F filing for Q3 2016, filed 14 Nov 2016.